Immunoglobulin E (IgE) specific for Juniperus virginiana pollen allergens (IgE (Juniperus virginiana))

Immunoglobulin E (IgE) antibodies specific for Juniperus virginiana (Eastern Red Cedar) pollen allergens are the primary mediators of Type I hypersensitivity reactions in sensitized individuals (WHO/IUIS Allergen Nomenclature, 2024). These antibodies are produced by B cells and subsequently bind with high affinity to the FcεRI receptors located on the surface of mast cells and basophils (Galli & Tsai, Nature Medicine, 2012). Upon subsequent exposure to Juniperus virginiana pollen, the allergens (such as the pectate lyase Jun v 1) cross-link the membrane-bound IgE, triggering the release of inflammatory mediators like histamine, leukotrienes, and cytokines (Janeway's Immunobiology, 9th ed.). This process leads to the clinical symptoms of allergic rhinitis, conjunctivitis, and potentially asthma (Bousquet et al., J Allergy Clin Immunol, 2001). Therapeutic strategies targeting this pathway include monoclonal antibodies like omalizumab, which sequester free IgE and downregulate FcεRI expression, and allergen-specific immunotherapy, which aims to induce immune tolerance and shift the antibody response from IgE to IgG4 (FDA Label: Xolair; Akdis & Akdis, 2014).

Other names

Eastern Red Cedar-specific IgEAnti-Jun v IgEJuniperus virginiana-specific IgECedar-specific IgE

Omalizumab binds to the Cε3 domain of free IgE, preventing its interaction with the high-affinity FcεRI receptor on mast cells and basophils, which subsequently leads to the downregulation of these receptors (FDA Label: Xolair). Allergen-specific immunotherapy (AIT) involves the administration of increasing doses of Juniperus virginiana allergens to induce immunological tolerance, characterized by the production of IgG4 blocking antibodies and the induction of regulatory T cells (Akdis & Akdis, 2014).